Title:Aloe-emodin: Progress in Pharmacological Activity, Safety, and
Pharmaceutical Formulation Applications
Volume: 24
Issue: 19
Author(s): Haimeng Luo, Xiaoyun Ji, Mengyu Zhang, Yaoyao Ren, Rui Tan*, Hezhong Jiang*Xiaoqing Wu*
Affiliation:
- School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China
- School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China
- School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China
Keywords:
Aloe-emodin, pharmacological, mechanism, pharmacokinetics, safety, nanoformulation, AE-based therapies.
Abstract: Aloe-emodin (AE) is an anthraquinone derivative and a biologically active component
sourced from various plants, including Rheum palmatum L. and Aloe vera. Known chemically as
1,8-dihydroxy-3-hydroxymethyl-anthraquinone, AE has a rich history in traditional medicine and is
esteemed for its accessibility, safety, affordability, and effectiveness. AE boasts multiple biochemical
and pharmacological properties, such as strong antibacterial, antioxidant, and antitumor effects.
Despite its array of benefits, AE's identity as an anthraquinone derivative raises concerns about its
potential for liver and kidney toxicity. Nevertheless, AE is considered a promising drug candidate
due to its significant bioactivities and cost efficiency. Recent research has highlighted that nanoformulated
AE may enhance drug delivery, biocompatibility, and pharmacological benefits, offering
a novel approach to drug design. This review delves into AE's pharmacological impacts, mechanisms,
pharmacokinetics, and safety profile, incorporating insights from studies on its nanoformulations.
The goal is to outline the burgeoning research in this area and to support the ongoing development
and utilization of AE-based therapies.